title: Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen.
abstract: Human telomerase reverse transcriptase (hTRT) is a potential target for therapeutic vaccination against cancer. Therefore, it is critically important to identify T cell epitopes useful to induce cytotoxic T cell responses. Here we used a positional scanning combinatorial peptide library to identify peptide analogues for a previously characterized low affinity hTRT peptide (p572). From an initial library containing over 300 billion different peptides and through successive rounds of selection, we retained 72 candidate peptide analogues for further assessment of antigenicity and in vivo immunogenicity in HLA A2.1-transgenic mice. While antigenically cross-reactive with p572, only a fraction of these peptides was immunogenic in mice. Immunogenicity appeared to correlate with the stability of binding to the MHC molecule and the presence of HLA A2.1 anchor residues in position 2 and 9. Two peptides differing by five residues from the reference p572 (p49 and p50) were more effective than p572 in inducing CTL cross-reacting with p572 in HLA A2.1-transgenic mice. Both peptides also expanded specific CTL in peripheral blood lymphocytes of normal human volunteers ex vivo. The present study shows that positional scanning combinatorial peptide libraries can be used to identify hTRT peptide analogues for inclusion in a cancer vaccine.
authors.affiliation: Department of Medicine and Cancer Center, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
authors.forename: Javier
authors.initials: J
authors.lastname: Hernández
authors.forename: Kim
authors.initials: K
authors.lastname: Schoeder
authors.forename: Sylvie E
authors.initials: SE
authors.lastname: Blondelle
authors.forename: Fancisco Garcia
authors.initials: FG
authors.lastname: Pons
authors.forename: Yu Chun
authors.initials: YC
authors.lastname: Lone
authors.forename: April
authors.initials: A
authors.lastname: Simora
authors.forename: Pierre
authors.initials: P
authors.lastname: Langlade-Demoyen
authors.forename: Darcy B
authors.initials: DB
authors.lastname: Wilson
authors.forename: Maurizio
authors.initials: M
authors.lastname: Zanetti
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D004268:DNA-Binding Proteins; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D019151:Peptide Library; D010455:Peptides / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019098:Telomerase / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D004268:DNA-Binding Proteins; D015395:Histocompatibility Antigens Class I; D019151:Peptide Library; D010455:Peptides; D019098:Telomerase